The BE CAR-33 asset represents a novel approach in the treatment of relapsed acute myeloid leukaemia (AML) in pediatric patients, utilizing base editing technology to enhance CAR T cell efficacy while minimizing off-target effects. The market for AML therapies is growing, driven by the increasing incidence of the disease and the demand for innovative treatments. Competitive implications include potential differentiation from existing CAR T therapies through its unique mechanism of action and safety profile. Diligence considerations should focus on the long-term follow-up data and the scalability of manufacturing the base-edited CAR T cells, as well as regulatory pathways given the innovative nature of the technology.